Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Melanoma
Stage/Subtype:  stage IIIB melanoma
Near ZIP Code:  within 200 miles of 21075
Results 1-25 of 39 for your search:
Start Over
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients with High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E1609, NCI-2011-02649, CDR0000692568, ECOG-E1609, NCT01274338
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 103A-301, NCI-2012-01351, NCT01546571
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-CA-P01, NCI-2015-00099, 2014-000544-15, 2015-001984-38, CL-CA-P01-00-US, NCT01875653
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6134, NCI-2014-01747, NCT02224781
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Phase: Phase III
Type: Treatment
Age: 18 to 95
Trial IDs: 20120166, NCI-2014-01975, NCT02147951
A Phase 1/2 Study to Evaluate MEDI4736
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CD-ON-MEDI4736-1108, NCI-2012-02062, NCT01693562
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20110264, NCI-2012-03087, NCT01740297
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2114, NCI-2013-01329, NCT01781572
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204, NCI-2015-00040, NCT02327078
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Dabrafenib, Trametinib, and Navitoclax in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-424, NCI-2013-02103, NCT01970956, 9466, NCT01989585
Dasatinib in Treating Patients with Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2607, NCI-2009-00532, CDR0000598300, ECOG-E2607, NCT00700882
Aldesleukin with or without Ziv-Aflibercept in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: PhII-107, NCI-2011-02498, CDR0000690654, CHNMC-PHII-107, 8628, NCT01258855
Ipilimumab with or without High-Dose Recombinant Interferon Alfa-2b in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E3611, NCI-2012-01932, CDR0000741878, ECOG-E3611, NCT01708941
Molecular Profiling-Based Targeted Therapy in Treating Patients with Advanced Solid Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0105, NCI-2013-01588, 130105, P121047, 9149, NCT01827384
INCB024360 and Vaccine Therapy in Treating Patients with Stage III-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-04, NCI-2013-01605, NCT01961115
Molecularly Targeted Therapy in Treating Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-184, NCI-2014-00670, 1144561, 1408014446, 161467, 1-822810-1, 1-835151-1, 1-866947-1, 193005, 20140190, Invest #161467, Study #1144561, WIRB Pro #20140190, WO #1-822810-1, NCT02094872
CDX-1401 and Poly-ICLC Vaccine Therapy with or without CDX-301in Treating Patients with Stage IIB-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-07-FLT3L, NCI-2014-00898, NCT02129075
Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1320, NCI-2014-01470, NCT02196181
A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CDX011-05, NCI-2015-00448, NCT02302339
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGK974X2101, NCI-2011-03693, 2011-000495-33, NCT01351103
Start Over